Introduction
Over the 74 years since the introduction of penicillin, our use and misuse of antibiotics in humans and animals has led to rising antibiotic resistance -to such an extent, that once commonly treatable bacteria are now either untreatable or require the last line of antibiotics.
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The movement of resistance genes between different bacterial species through plasmid-mediated horizontal gene transfer increases the variety of bacterial populations possessing multidrug-resistant (MDR) potential, and the intense selection pressure exerted by antibiotics selects out antibioticresistant bacteria capable of causing infection in humans and animals. 3 The recent identification of new plasmid-mediated resistance genes conferring colistin resistance in bacterial isolates from food animals has re-ignited the debate concerning the contribution of antibiotic consumption in animals to levels of resistance in humans. 4 Although pertinent to all antibiotics, resistance to colistin is of particular concern as it plays the role of 'antibiotic of last resort' against common Gram-negative bacterial infections that are now increasingly MDR. 5 The shift in patterns of colistin resistance and how we should respond are examined and discussed in this review.
the time they take to perform. [6] [7] [8] [9] [10] [11] [12] [13] Broth microdilution is considered the reference standard for polymyxin susceptibility testing. The Etest, agar dilution, and broth microdilution assays are generally concordant, although discordance of Etest and agar dilution with broth microdilution has been reported. 14, 15 16 Definite breakpoints for colistin susceptibility have been established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). 17 The Clinical and Laboratory Standards Institute (CLSI) has also provided susceptibility criteria for Pseudomonas and Acinetobacter. 18 
Chromosomally mediated colistin resistance
The recent identification of plasmid-mediated colistin resistance mechanisms has extended our understanding of colistin resistance that has been chromosomally mediated, with vertical transmission and slow evolution. [19] [20] [21] Colistin resistance is thought to relate to lipopolysaccharide modification via changes in the mcrB gene and upregulation of PhoP/PhoQ. 4, [22] [23] [24] The worldwide prevalence of resistance to polymyxins is about 10% among Gram-negative bacteria and is highest in Mediterranean countries and Southeast Asia. 25 
Plasmid-mediated colistin resistance
Plasmid-mediated colistin resistance encoded by mcr-1, a gene of the phosphoethanolamine transferase enzyme family, was first documented in China during the routine surveillance of food animals. 20 A retrospective analysis of 1611 isolates of Escherichia coli from chicken farms showed that the earliest mcr-1-harboring isolate was from the 1980s when colistin was first used for livestock in China. 26 Since then, mcr-1 has been identified in isolates from humans, animals, and the environment in an increasing number of countries (Table 1) . 20, 21, In keeping with other resistance mechanisms, mcr-1 is capable of travelling with its human host; 10% of 38 travelers from India were found to harbor mcr-1 resistant E. coli in stool. 55 The identification of mcr-1-mediated colistin resistance in E. coli and Klebsiella pneumoniae in pilgrims attending the annual Hajj indicates a risk for acquisition in those attending mass gatherings. 60 The initial description of mcr-1 was in 21% of healthy swine at slaughter, 15% of marketed pork and chicken meat, and 1% of hospitalized patients in China. 20 The first human isolate was detected in E. coli in Latin America. 46 In the SENTRY program, 5% of clinical isolates of E. coli and K. pneumoniae were found to carry mcr-1 resistance. 105 K. pneumoniae with variant mcr-1 resistance was also isolated from a rectal swab of an Italian child. 34 Lastly, resistant isolates carrying mcr-1 were described in 11 Salmonella from clinical samples, food, and water in Portugal, 106 and in Shigella sonnei from Vietnam. 96 Recently, mcr-2, another phosphoethanolamine transferase plasmid-mediated colistin resistance gene, which shares 76.7% nucleotide sequence homology to mcr-1, was isolated from porcine and bovine E. coli.
21 mcr-2 was identified in 21% of porcine colistinresistant E. coli in Belgium compared with 13% with mcr-1.
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The co-localization of mcr-1 with other resistance mechanisms highlights the fact that discussions regarding the stewardship of antibiotics across the One Health platform are not only pertinent to antibiotics of last resort such as colistin, but also to more commonly used antibiotics. There have been a number of reports of co-localization of mcr-1 with carbapenemases and/or extendedspectrum b-lactamase (ESBL); mcr-1 and bla NDM-5 , a metallo-blactamase, were transferred by an IncX3-X4 hybrid plasmid. 54 A similar finding was reported from a patient with a urinary tract infection in the USA. 65 mcr-1 has also been found to be associated with ESBL-producing isolates bearing bla CTX-M-1 and a human isolate with a bla KPC-2 carbapenemase gene. 37, 81, 92, 98 In addition, the mcr-1 gene co-localizes with multiple plasmid replicon types: IncI2, IncHI2, IncP, IncFIP, and IncX4. 43, 81, 107 These plasmids are associated with resistance to quinolones and may acquire genes conferring resistance to cephalosporin (bla CTX-M-14 ) and fosfomycin (fosA3). 108 The coexistence of mcr-1 with other resistance genes indicates the existence of different pathways for the horizontal transmission of colistin resistance. 37 One isolate had bla NDM-9 , fosA3, rmtB, bla CTX-M-65 , and floR thus confirming resistance to carbapenems, fosfomycin, aminoglycoside, cephalosporin, and florfenicol, respectively. 109 Resistant mcr-1 isolates to colistin, polymyxin B, cephalosporin, gentamicin, and ciprofloxacin are thought to have been transmitted from animals to humans. 90 The coexistence of these genes with high potential of spread is of great concern. It is also important to keep in mind that these genes may be present in strains that are relatively susceptible to other antibiotics, but as they are reported as susceptible, colistin resistance is unlikely to be routinely tested for.
Avoiding the blame game
Due to the status of colistin as the 'antibiotic of last resort' for Gram-negative bacteria in humans, its use across the One Health platform has come under intense scrutiny, and a climate of blame has been generated, mainly directed towards farmers and veterinarians. 110, 111 It is assumed that plasmid-mediated colistin resistance moved from animals to humans, based on the fact that mcr-1 and mcr-2 predominate in animals and were first described in animals, which as a group, consume the largest volume of that antibiotic. 28 However, the intense overuse and misuse of antibiotics such as colistin across the One Health platform is driving selection pressure, and it is therefore a collective, unified reduction in total antibiotic use that must be focused upon. 112 The human consumption of colistin is itself a marker of overuse and misuse of all antibiotics, which have systematically been rendered ineffective by stepwise selection out of increasingly resistant bacteria, resulting in the need to use 'the last man standing', i.e., colistin.
In livestock, colistin (and the vast majority of total antibiotic use) has historically spoken to a simple need: an expanding global population that requires food security in terms of animal protein. 113 To ensure this, sub-therapeutic concentrations of antibiotics have been used for decades to promote animal growth, and treatment doses are used for large-scale prophylaxis (metaphylaxis) to protect healthy feed animals from infection. In contrast, much smaller volumes are used for the individual treatment of sick animals. 114 Approximately 12 000 tons of colistin is estimated to be used per year in 2015 in food production, with consumption expected to rise to 16 500 tons by 2021. 20 [ 4 _ T D $ D I F F ] These volumes may be underestimates because surveillance data are lacking for many countries. The key to unlocking this conundrum is preventing infection in humans and animals to reverse the continued reliance on antibiotics to perform the task that tackling the social determinants of infection would achieve. In human public health, this relates to the provision of clean water and sanitation to reduce diarrheal diseases, ensuring global access to immunization against bacterial and viral illnesses that drive the use of antibiotics, and the promotion of uniform practices of infection prevention and control in healthcare establishments to prevent healthcare-associated infections and the transmission of bacteria between patients through poor hand hygiene.
Experience from the European Union since the ban on animal growth promoters (AGP) in 2006 suggests that improving biosecurity, biosafety, and the diet of livestock could render the need for AGPs obsolete and significantly reduce the need for metaphylaxis, reserving it for the protection of healthy animals only when others in the group become sick. 114 Furthermore, cleaning and disinfection between meat production cycles is an important public health intervention in food production to limit the spread and accumulation of resistance genes in the following cycles. [115] [116] [117] Lastly, the companion animal-human axis should not be ignored. A study by Zhang et al. has recently highlighted the transmission of E. coli carrying mcr-1 between companion animals and humans. 90 
How should we respond?
According to the US Centers for Disease Control and Prevention (CDC), ''the One Health concept recognizes that the health of humans is connected to the health of animals and the environment''. 118 Another definition is ''the collaborative effort of multiple disciplines working locally, nationally, and globally to attain optimal health for people, animals and our environment''. 119 The
One Health program relies on three pillars: human health, livestock or aquaculture, and environmental health. 120 Understanding the relative importance of the contribution of each component is important in tackling antimicrobial resistance.
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A One Health approach to decrease the consumption of all antibiotics is the goal. 121, 122 To protect food security, phasing out antibiotic use for AGP and metaphylaxis in favor of heightened infection prevention and nutrition interventions will take time. However, critical antibiotics required for human use, such as colistin, should be protected by an immediate cessation of use in livestock, as has been announced by the Responsible Use of Medicines in Agriculture (RUMA) alliance 123 and China. 124 This must be done in concert with restrictions in human use: restricting colistin for definitive treatment based on susceptibility testing, or to empirical use in clearly defined circumstances, coupled with attention to pharmacokinetics and pharmacodynamics to ensure optimal dosing, must be part of every country's national action plan. Ambitious targets should be set by each country to reduce overall consumption. 125 In terms of dosing, high doses of up to 720 mg (9 million IU) per day are employed, 126, 127 and the need for a loading dose has been highlighted. 128, 129 Under-dosing colistin in patients with critical illness, burns, renal failure, and obesity risks the emergence of resistance. 130 Resistant strains have been reported in burn patients, 130 and critically ill patients on continuous venovenous hemodiafiltration require higher doses. 131 There have been no prospective studies evaluating the optimal dosing of colistin to limit side effects and provide the best bactericidal effect. It is feared that doses that result in sub-optimal bactericidal colistin concentrations may lead to the selection of resistant bacteria. 132, 133 In a retrospective observational study of 72 patients with MDR Gram-negative pneumonia, the clinical cure rate was 55% in those receiving a regular dosing regimen compared to 67% in those receiving a loading dose and high-dose maintenance regimen. 134 As with other antibiotics, prior use of colistin is itself a risk factor for the development of resistance. 135 In a study of 20 patients, both colistin-susceptible and colistin-resistant Acinetobacter from the same patients were found to be highly related by pulsed-field gel electrophoresis (PFGE), indicating the development of resistance during colistin treatment. 136 In a further study of 41 colistin-resistant isolates, colistin was the only independent risk factor for such resistance. 137 The enteral use of colistin for selective gastrointestinal decontamination has been associated with the emergence of colistin resistance. 138 However, this resistance is thought to be secondary to sub-therapeutic colistin doses. 139, 140 Ultimately, the action we take to protect human health, which relies just as much on food security as it does on antibiotics to treat serious bacterial infections, must be translatable to all antibiotics (and indeed all antimicrobials), including the new antibiotics to come. The proposed global stewardship framework, which will lay out how we steward a new antibiotic to ensure equity of access and define the working parameters for how it should be used, must be enforceable and countries must be accountable for their protection. A United Nations-led coordinating mechanism, as agreed at the UN General Assembly in September 2016, provides an opportunity to define a true One Health approach to antibiotic consumption and to set up monitoring and evaluation mechanisms to ensure countries comply. 141 This will be essential if we are to conserve colistin pending the development of new antibiotics to treat MDR Gram-negative bacteria. 
